Boothbay Fund Management, LLC Reata Pharmaceuticals Inc Call Options Transaction History

Boothbay Fund Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $150,518 - $200,203	1,900 Added 9.36%	22,200 $2.26 Million
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $626,255 - $1.89 Million	20,300 New	20,300 $1.85 Million
Q3 2022 Nov 14, 2022	SELL	$19.41 - $36.49 $36,879 - $69,331	-1,900 Reduced 9.27%	18,600 $467,000
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $26,923 - $47,450	-1,300 Reduced 5.96%	20,500 $623,000
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $279,149 - $1.21 Million	10,900 Added 100.0%	21,800 $575,000
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $1.09 Million - $1.56 Million	10,900 New	10,900 $1.1 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.